BALA CYNWYD, Pa., April 2, 2012 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of ISTA
Pharmaceuticals, Inc. ("ISTA" or the "Company") (NASDAQ: ISTA)
relating to the proposed acquisition by Bausch & Lomb.
Under the terms of the transaction, ISTA shareholders would
receive only $9.10 in cash for each
share of ISTA stock they own. The investigation concerns possible
breaches of fiduciary duty and other violations of state law by the
Board of Directors of ISTA for not acting in the Company's
shareholders' best interests in connection with the sale process to
Bausch & Lomb. The transaction may undervalue ISTA as ISTA
stock traded at $11.26 on
May 10, 2011. In addition, the medium
analyst price target for ISTA stock was $10.50 per share and an analyst has set a price
target on ISTA stock at $12.00 per
share.
If you own shares of ISTA stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L.
Brodsky, Esquire or Evan J. Smith,
Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by
e-mail at investorrelations@brodsky-smith.com, visiting
http://brodsky-smith.com/402-ista-ista-pharmaceuticals-inc.html, or
by calling toll free 877-LEGAL-90.
SOURCE Law office of Brodsky & Smith, LLC